Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2

Clinical and animal studies have suggested a possible beneficial effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH). Although SGLT2 inhibitors have been shown to reduce hepatic fat deposition in associ...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Biochemical and biophysical research communications 2021-06, Vol.557, p.62-68
Hauptverfasser:	Yoshino, Kei, Hosooka, Tetsuya, Shinohara, Masakazu, Aoki, Chikako, Hosokawa, Yusei, Imamori, Makoto, Ogawa, Wataru
Format:	Artikel
Sprache:	eng
Schlagworte:	Canagliflozin Lipid mediator Nonalcoholic fatty liver disease (NAFLD) Nonalcoholic steatohepatitis (NASH) Prostaglandin E2 (PGE2) SGLT2 inhibitor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!